Citations

Clear

13603 citation(s) found for "_, _".

The Impact of Program and Geographic Signaling on Anesthesia Residency Applications, Interviews, and the Match
Dutoit, Andrea P. , Teeter, Emily G. , Wolpaw, Jed , Martin, Timothy W. , Manohar, Crystal , Long, Timothy R. , Abramowicz, Apolonia E. , Stahl, David L. , Shostrom, Valerie , Hoffman, Julie, Martinelli, Susan M. , Hoffman, Julie T.

Mayo Clinic

Anesthesia & Analgesia | February 7, 2025 | Volume: 141 | Issue: 4 | Pages: 876-883

10.1213/ane.0000000000007443 | PMID 39919023 Get It

BACKGROUND: Increased specialty competitiveness, alongside the inception of virtual interviews, has increased the number of applications submitted to the Electronic Residency Application Service (ERAS) in anesthesiology. ERAS introduced signals to provide applicants with a means to demonstrate interest in a select group of residency programs. In the 2023 to 2024 application cycle, anesthesiology applicants had the opportunity to send 5 gold and 10 silver signals in a tiered system. METHODS: This multicenter, cross-sectional (exempt) research survey was created by members of the executive council of the Association of Anesthesiology Core Program Directors (AACPD) and housed and distributed through REDCap and the University of Nebraska Medical Center. Publicly available contact information of anesthesiology core program directors was obtained from the Accreditation Council for Graduate Medical Education (ACGME) website and membership roster of the AACPD. In total, 174 anesthesiology programs were identified. A survey invitation was distributed on March 12, 2024, to all programs via e-mail with reminders. The survey closed on April 30, 2024. Survey responses were collected anonymously, with instructions to provide 1 response per program. All statistical summaries and analyses were performed using SAS 9.3 (SAS Institute). RESULTS: The survey was sent to all 174 identified programs, with a response rate of 48.9%. Small programs were defined as having <44 residents, medium 44 to 62 residents, and large >62 residents. Small programs received significantly fewer applications (median 1255) than medium (1420) and large (1558) programs ( P = .0005). There was a statistically significant difference in the number of gold signals received based on program size, with large programs receiving significantly more than medium (169 vs 116, P = .0238) or small programs (168 vs 71, P < .0001). Applicants sending gold signals were more likely to receive an interview compared to those who sent silver signals (56.7% vs 31%, P ≤ .0001). Of the those interviewed, applicants who sent gold signals comprised 42% (28.7%–52.6%), whereas applicants who sent silver signals comprised 45.5% (33%–54.7%). Applicants who did not send a program signal but signaled geographically made up a smaller portion of the interview group at 3% (0%–15.4%). The percentage of matched residents sending gold signals made up 66.7% (47.1%–82.4%) of a program’s match list, whereas those sending silver signals were 25% (11.1%–33.3%) of the matched cohort. CONCLUSIONS: Anesthesiology applicants who sent program signals were selected for a large majority of available interview positions, and interviewed applicants who submitted gold and silver signals comprised the vast majority of matched resident cohorts.
Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study
Luskin, Marlise R. , Yin, Jun , Lozanski, Gerard , Curran, Emily , Malnassy, Gregory , Mrózek, Krzysztof , Bloomfield, C. D., Fulton, Noreen, Kolitz, Jonathan E. , LaPlant, Betsy, Kour, Oudom, Powell, Bayard L., Vij, Ravi , Grinblatt, David L. , Stone, Richard M. , Wang, Eunice S. , Larson, Richard A , Luskin, Marlise R , Cataland, Spero R. , Uy, Geoffrey L. , Larson, Richard A. , Stock, Wendy

Mayo Clinic

Cancer | February 7, 2025 | Volume: 131 | Issue: 4 | Pages: No page available

10.1002/cncr.35750 | PMID 39916320 Get It

AbstractBackgroundAcute lymphoblastic leukemia (ALL) in adults is aggressive, with long‐term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B‐ and T‐lineage ALL. Alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that targets CD52, was identified as a potential agent to improve treatment efficacy without increasing toxicity.MethodsIn this phase 1/2 study (Cancer and Leukemia Group B [CALGB] 10102, NCT00061945), a course of single‐agent alemtuzumab was intercalated into CALGB 19802 backbone chemotherapy after the third course of intensive chemotherapy in those who were CD52+ at diagnosis. Phase 1 tested three dose levels of subcutaneous alemtuzumab (10, 20, and 30 mg 3 times weekly for 4 weeks/12 doses) and demonstrated that 30 mg was tolerable. Phase 2 established feasibility.ResultsThe study enrolled 295 evaluable patients (115 in phase 1, 180 in phase 2); 206 (69.8%) were CD52+. Among evaluable CD52+ patients, 43.7% (90/206) completed the first three treatment modules; 97.8% (88 of 90) were treated with alemtuzumab. Alemtuzumab was associated with cytomegalovirus viremia, which occurred in 23.3% (14 of 60) of patients during and 29.2% (19 of 65) after alemtuzumab treatment. With a median follow‐up of 101.2 months, median overall survival (OS) was 26.3 months (3‐year rate, 44%; 5‐year rate, 36%; 10‐year rate, 31%). Landmark analysis at the start of the fourth course of treatment demonstrated no difference in OS or disease‐free survival between patients who did and who did not receive alemtuzumab.ConclusionAlemtuzumab was feasible to administer in adults with ALL receiving intensive chemotherapy, but was without evidence of benefit.
Efficacy and safety of preoperative embolization in surgical treatment of brain arteriovenous malformations: a multicentre study with propensity score matching
Salim, Hamza , Hamdan, Dawoud, Adeeb, Nimer , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S. , Dmytriw, Adam A. , Ataoglu, Cagdas , Erginoğlu, Ufuk , Naamani, Kareem El, Sheehan, Jason P. , Ironside, Natasha , Gummadi, Sanjeev, Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Sen, Rajeev , Başkaya, Mustafa K. , Tjoumakaris, Stavropoula , Atallah, Elias , Riina, Howard A. , Abushehab, Abdallah, Swaid, Christian, Burkhardt, Jan‐Karl , Starke, Robert M., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Abla, Adib A. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Cochran, Joseph, Pukenas, Bryan , Smith, Edward R. , Moehlenbruch, Markus, Alaraj, Ali , Patel, Aman B. , Yedavalli, Vivek , Cuellar, Hugo H, Lawton, Michael T. , Guthikonda, Bharat , Aslan, Assala , Musmar, Basel , Ogilvy, Christopher S , Dmytriw, Adam A , Essibayi, Muhammed Amir , Alwakaa, Omar , Griessenauer, Christoph J , Jabbour, Pascal , Altschul, David J , Koch, Matthew J , Chen, Peng R , Orbach, Darren B , Alaraj, Ali , Yedavalli, Vivek S , Abla, Adib , Salim, Hamza , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Hamdan, Dawoud , Kandregula, Sandeep , Abdelsalam, Ahmed , Kondziolka, Douglas , Naamani, Kareem El , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Rezai, Arwin, Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Jabbour, Pascal , Sekhar, Laligam N. , Levitt, Michael R. , Blackburn, Spiros , Choudhri, Omar , Orbach, Darren B. , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Wintermark, Max , Savardekar, Amey Rajan , Morcos, Jacques J.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | February 6, 2025 | Volume: 96 | Issue: 8 | Pages: 766-774

10.1136/jnnp-2024-334974 | PMID 39915091 Get It

Background Brain arteriovenous malformations (AVMs) are abnormal connections between feeding arteries and draining veins, associated with significant risks of haemorrhage, seizures and other neurological deficits. Preoperative embolization is commonly used as an adjunct to microsurgical resection, with the aim of reducing intraoperative complications and improving outcomes. However, the efficacy and safety of this approach remain controversial. Methods This study is a subanalysis of the Multicenter International Study for Treatment of Brain AVMs consortium. We retrospectively analysed 486 patients with brain AVMs treated with microsurgical resection between January 2010 and December 2023. Patients were divided into two groups: those who underwent microsurgery alone (n=245) and those who received preoperative embolization, followed by microsurgery (n=241). Propensity score matching was employed, resulting in 288 matched patients (144 in each group). The primary outcomes were rates of complete AVM obliteration and functional outcomes (measured by the modified Rankin Scale (mRS)). Secondary outcomes included complication rates, mortality, hospital length of stay and postsurgical rupture. Results After matching, the complete obliteration rate was 97% with no significant difference between the microsurgery-only group and the preoperative embolization group (p=0.12). The proportion of patients with an mRS score of 0–2 at the last follow-up was similar in both groups (83% vs 84%; p=0.67). The median hospital stay was significantly longer for the embolisation group (9 days vs 7 days; p=0.017). Complication rates (24% vs 22%; p=0.57) and mortality rates (4.9% vs 2.1%; p=0.20) were comparable between the two groups. No significant differences were observed in postsurgical rupture, recurrence or retreatment rates. Conclusions In this large multicentre study, preoperative embolization did not significantly improve AVM obliteration rates, functional outcomes or reduce complications compared with microsurgery alone.
Patient Experience of Awake Laryngoscopy Procedures
Hsu, Andrea R. , Johns, Heather L., Arguelles, Ivonne, O'Byrne, J, Ekbom, Dale C. , Orbelo, Diana M. , Bayan, Semirra L. , O'Byrne, Jamie, Orbelo, Diana, Bayan, Semirra , Orbelo, Diana , O’Byrne, Jamie

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | February 6, 2025 | Volume: 134 | Issue: 6 | Pages: 392-404

10.1177/00034894251315339 | PMID 39910839 Get It

Objective(s): To quantify and compare pre-procedure worry versus the experience of pain, gagging, and dyspnea during in-office laryngoscopy procedures in patients who did or did not receive pre-procedure anxiolytics, and to explore patient perception of intra-procedure interventions. Methods: Patients undergoing awake laryngology procedures at a quaternary care center were enrolled. The State-Trait Anxiety Inventory (STAI) Y1 and Y2 questionnaires were administered to establish baseline levels of state anxiety and trait anxiety, respectively. Pre-procedure and post-procedure surveys assessed patient perception of select interventions. Results: 34 patients were enrolled (35.3% female, 91.2% white, mean age 60 years). Pre-procedure, 51.5% of patients reported some degree of worry about pain, 61.8% about gagging, 52.9% about dyspnea, and 55.9% about having something in their nose/throat. Post-procedure, 54.5% reported experiencing pain to some degree, 63.6% had gagging, 39.4% had dyspnea, and 78.7% were bothered by having something in their nose/throat. Patients who received a pre-procedure anxiolytic were significantly more likely to report more pain compared to those who did not. The highest rated interventions were pre-procedural education (97.0% “Very helpful”), verbal reassurance (96.9%), provider communicating steps of the procedure (96.9%), and reminders to breathe (87.5%). Conclusion: For patients undergoing awake laryngology procedures, the anticipation of gagging, pain, trouble breathing, and scope-related discomfort are worrisome factors. Of these, scope-related discomfort and gagging are the most often-reported sources of intraprocedural discomfort. The interventions patients found most helpful were based on preprocedural education and clear intraprocedural communication, which suggests that purposeful communication has a role in relieving anxiety. Level of evidence: Level 4
Family Medicine Residency Faculty: Inpatient Staffing, Satisfaction, and Turnover
Furlano, Anthony, Nordin, Terri , Ruppel, Lindsey M., Smith, Emily R, Furlano, Anthony J, Hidaka, Brandon H. , Smith, Emily R., Waheed, Abdul A

Mayo Clinic

Family Medicine | February 5, 2025 | Volume: 57 | Issue: 4 | Pages: 276-285

10.22454/fammed.2025.822335 | PMID 40272870 Get It

Background and Objectives: Physician scheduling affects job satisfaction and retention. This study explores how family medicine residency inpatient staffing relates to core faculty retention and program director (PD) perception of faculty satisfaction with work-life integration. Methods: A total of 280 family medicine residency PDs responded to the 2023 Council of Academic Family Medicine Education Research Alliance survey. We used the ꭓ2 test to explore associations among program demographics, inpatient staffing characteristics, faculty retention, and PD-reported faculty satisfaction with work-life integration. We measured associations among pairs of ordinal variables with Spearman’s correlation. Results: In two-thirds (66%) of programs, faculty cover the inpatient service at least every 8 weeks, with 40% of programs reporting averages of 70 or more hours per inpatient week; nevertheless, most programs’ faculty were perceived to be satisfied with less than 10% turnover. The number of hours per week was inversely associated with PD-reported faculty satisfaction (r=-0.21, P=.001). Faculty turnover was directly associated with community size (r=0.17, P=.01). Faculty turnover was more likely to be greater than 10% if the number of hours per inpatient week was more than 89 (odds ratio 12.4, P=.02). Faculty turnover, PD-reported faculty dissatisfaction, and plans to change inpatient staffing were all correlated (r&gt;0.28, P&lt;.0001). Conclusions: Most family medicine residencies have core faculty cover the inpatient service at least once every 8 weeks, during which they work at least 60 hours per week. Longer hours are associated with lower perceived faculty satisfaction of work-life integration, with a threshold effect on faculty turnover. Family medicine residency programs must carefully balance the needs of residents, the community served, and faculty themselves.
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Wood, Cameron , Lyniv, Liliana, Isaacs, James M, Kaufman, Jacob M., Oduah, Eziafa , Clarke, Jeff, Crawford, Jeffrey, Stinchcombe, Thomas E. , Tong, Betty , Wigle, Dennis A. , Dragnev, Konstantin H. , Antonia, Scott , Ready, Neal , Wigle, Dennis, Ready, Neal , Wood, Cameron , Isaacs, James , Wang, Xiaofei , Gu, Lin, Weinhold, Kent J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | February 4, 2025 | Volume: 13 | Issue: 2 | Pages: e010395

10.1136/jitc-2024-010395 | PMID 39904561 Get It

Background Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC. Methods This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, clinical stage IB to IIIA NSCLC. Patients received two doses of 200 mg pembrolizumab, surgery, standard adjuvant chemotherapy, followed by four doses adjuvant pembrolizumab. The primary objective of this study was to determine surgical feasibility rate, and secondary objectives are pathological response rate, treatment adverse events, efficacy data, and exploratory analysis of biomarkers. Results 30 patients initiated perioperative pembrolizumab, and 25 completed tumor resection. At median follow-up of 59 months after surgical resection, seven patients had disease progression, while six had died representing. A 5-year progression-free survival (PFS) from time of surgery was 72.0% (56.4%–91.9%) and overall survival (OS) from time of surgery was 75.8% (60.7%–94.7%). Major pathological response (MPR) was found in seven tumors (28%) including two complete responses (4%). Across all treated patients, four receiving neoadjuvant and four receiving adjuvant pembrolizumab experienced treatment-related adverse events of grade 3 or higher with no grade 5 events. Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels increased across our patient cohort over time from baseline until postsurgery and remained elevated at the end of treatment. There was a significant difference between mean plasma PCSK9 levels for patients with MPR versus all other patients on study when checked postoperatively. Conclusions Perioperative pembrolizumab was safe and effective with promising MPR rate, PFS, and OS.
Waist Circumference, a Body Shape Index, and Molecular Subtypes of Colorectal Cancer: A Pooled Analysis of Four Cohort Studies
Chalitsios, Christos V. , Markozannes, Georgios , Papagiannopoulos, Christos , Aglago, Elom K. , Berndt, Sonja I. , Buchanan, Daniel D. , Campbell, Peter T. , Chan, Andrew T. , Dimou, Niki , Drew, David A. , French, Amy J. , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B. , Harrison, Tabitha A. , Hullar, Meredith A.J. , Huyghe, Jeroen R. , Newton, Christina C. , Obón‐Santacana, Mireia , Schmit, Stephanie L. , Steinfelder, Robert S. , Zaidi, Syed Hassan Ejaz , Peters, Ulrike , Phipps, Amanda I. , Cao, Yin , Chan, Andrew T , Dimou, Niki , Drew, David A , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B , Gunter, Marc J , Harrison, Tabitha A , Hoffmeister, Michael , Hsu, Li , Huang, Wen-Yi , Hullar, Meredith A , Huyghe, Jeroen R , Lynch, Brigid M , Moreno, Victor , Newton, Christina C , Nowak, Jonathan A , Obón-Santacana, Mireia , Ogino, Shuji , Qu, Conghui , Schmit, Stephanie L , Steinfelder, Robert S , Sun, Wei , Thomas, Claire E , Toland, Amanda Ewart , Trinh, Quang M , Ugai, Tomotaka , Um, Caroline Y , Van Guelpen, Bethany , Zaidi, Syed H , Murphy, Neil , Peters, Ulrike , Phipps, Amanda I , Tsilidis, Konstantinos K , Buchanan, Daniel D , Campbell, Peter T , Aglago, Elom K , Markozannes, Georgios , Cao, Yin , Gunter, Marc J. , Hoffmeister, Michael , Huang, Wen‐Yi , Moreno, Vı́ctor , Nowak, Jonathan A. , Qu, Conghui , Sun, Wei , Thomas, Claire E. , Trinh, Quang M. , Um, Caroline Y. , Guelpen, Bethany Van , Murphy, Neil , Tsilidis, Konstantinos K.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 3, 2025 | Volume: 34 | Issue: 4 | Pages: 568-577

10.1158/1055-9965.epi-24-1534 | PMID 39898780 Get It

Abstract Background: Waist circumference (WC) and its allometric counterpart, “a body shape index” (ABSI), are risk factors for colorectal cancer; however, it is uncertain whether associations with these body measurements are limited to specific molecular subtypes of the disease. Methods: Data from 2,772 colorectal cancer cases and 3,521 controls were pooled from four cohort studies within the Genetics and Epidemiology of Colorectal Cancer Consortium. Four molecular markers (BRAF mutation, KRAS mutation, CpG island methylator phenotype, and microsatellite instability) were analyzed individually and in combination (Jass types). Multivariable logistic and multinomial logistic models were used to assess the associations of WC and ABSI with overall colorectal cancer risk and, in case-only analyses, to evaluate heterogeneity by molecular subtype, respectively. Results: Higher WC (ORper 5 cm = 1.06, 95% confidence interval, 1.04–1.09) and ABSI (ORper 1-SD = 1.07, 95% confidence interval, 1.00–1.14) were associated with elevated colorectal cancer risk. There was no evidence of heterogeneity between the molecular subtypes. No difference was observed regarding the influence of WC and ABSI on the four major molecular markers in proximal colon, distal colon, and rectal cancers, as well as in early- and late-onset colorectal cancers. Associations did not differ in the Jass-type analysis. Conclusions: Higher WC and ABSI were associated with elevated colorectal cancer risk; however, they do not differentially influence all four major molecular mutations involved in colorectal carcinogenesis but underscore the importance of maintaining a healthy body weight in colorectal cancer prevention. Impact: The proposed results have potential utility in colorectal cancer prevention.
Pancreatitis, Panniculitis, and Polyarthritis Syndrome as an Indication for Endoscopic Retrograde Cholangiopancreatography
Ajose, Idowu, Mills, Krystal , Hilscher, Moira

Mayo Clinic

ACG Case Reports Journal | February 1, 2025 | Volume: 12 | Issue: 2 | Pages: e01605

10.14309/crj.0000000000001605 | PMID 39901881 Get It

ABSTRACT Pancreatic diseases, including pancreatitis, may be associated with skin manifestations, and prompt recognition is crucial for diagnosis and prognosis. Pancreatic panniculitis is an uncommon dermatologic condition occurring in only 0.3%–3% of pancreatic diseases. Very rarely, the triad of pancreatitis, panniculitis, and polyarthritis syndrome can be observed. Of the scant cases in the literature, most patients received treatment with nonsteroidal anti-inflammatory drugs and/or steroids. To our knowledge, this is the first case to outline an endoscopic approach for pancreatitis, panniculitis, and polyarthritis syndrome in the setting of a pseudocyst.
Identification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer
Bassoy, Esen Yonca , Rubino, Thomas E. , Goergen, Krista M., Magtibay, Paul M. , Butler, Kristina , Schmitt, Alessandra C. , Oberg, Ann L. , Curtis, Marion , Raja, Remya , Goergen, Krista, Schmitt, Alessandra, Curtis, Marion , Coscia, Fabian

Mayo Clinic

OncoImmunology | February 1, 2025 | Volume: 14 | Issue: 1 | Pages: No page available

10.1080/2162402x.2025.2460276 | PMID 39891409 Get It

1421: DISSEMINATED INTRAVASCULAR COAGULATION, A COMPLICATION OF PERCUTANEOUS RENAL BIOPSY
Mukhtar, Mantasha, Rao, Bassam, Khan, Syed Anjum , Patel, Mikin , Imtiaz, Reem, Hanson, A., Yousuf, Zehra, Varriale, Brittany, Rao, Bassam, Patel, Milen, Imtiaz, Reem, Hanson, Arthur, Yousuf, Zehra

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001104348.97905.06 Get It